Status:
WITHDRAWN
Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence
Lead Sponsor:
Elizabeth Ralevski
Conditions:
Alcohol Dependence
Borderline Personality Disorder
Eligibility:
All Genders
21-60 years
Phase:
PHASE3
Brief Summary
The objective of the present study is to evaluate the efficacy of topiramate (250mg/day) versus placebo in decreasing aggression and reducing alcohol consumption in patients with borderline personalit...
Detailed Description
Background: Borderline personality disorder (BPD) affects about 2% of the American adult population. It is a very serious psychiatric disorder that places heavy demands on mental health resources. Beh...
Eligibility Criteria
Inclusion
- Diagnosis of AD
- Diagnosis of BPD
Exclusion
- Serious or unstable medical condition
- Opiate dependence
- Major Axis I disorder (bipolar disorder, schizophrenia)
- Taking mood stabilizers and antipsychotic medications
- LFT abnormalities that do not exceed 3 times normal values
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00463775
Start Date
March 1 2007
End Date
May 1 2009
Last Update
January 31 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.